Acute renal failure in four Comrades Marathon runners ingesting the same electrolyte supplement: Coincidence or causation? by Boulter, Jeremy et al.
The 89 km Comrades Marathon historically reports the highest 
incidence of acute renal failure (ARF) cases in any sporting event in 
the world (estimated at 2/10 000 runners).1 The first 2 cases reported 
from the event (in 1967 and 1968) occurred in races with only ~600 
runners.2 An incidence as high as 10/10 000 runners was reported 
in the 1986 Comrades Marathon.1 The spectrum of reported cases 
from this ultramarathon has ranged from unrecognised ARF that 
persisted for 10 days post-race3 to significant renal damage requiring 
extended hospitalisation and peritoneal dialysis.4 Aetiology factors 
proposed include dehydration secondary to inadequate fluid intake 
and/or diarrhoea or vomiting,1,2,4,5 rhabdomyolysis2,6 and analgesic 
use including paracetomol4 and non-steroidal anti-inflammatory 
drugs (NSAIDs).5
Forty years after the first description of ARF in Comrades 
Marathon runners,2 we report a cluster of 4 cases that occurred in 
the 2010 Comrades Marathon, and analyse possible causative factors. 
Methods
Four runners identified with ARF following their participation 
in the 2010 Comrades Marathon were brought to the attention 
of the event’s Chief Medical Officer (JB) by the head trauma unit 
physician at St Augustine’s Hospital, Durban – the referral hospital 
for the event in 2010. Verbal and written consent for the release of all 
hospital medical records was obtained from the runners by the first 
author in his capacity as Chief Medical Officer. He interviewed each 
runner within 2 weeks of hospital release about their medical history, 
running history, prior injuries, supplement and medication intake 
(before, during and after the run), and symptoms encountered during 
and after the race.
Results 
Of 16 500 participants, 14 343 completed the 89.3 km 2010 Comrades 
Marathon under the 12 hour cut-off (80% male; 26% novices). The 
average temperature in Durban was 19ºC (min 14ºC; max 24ºC) with 
63% humidity and 3 km/h wind speed. 
The average age of the 4 runners who developed ARF was 35±6 years 
(mean ± SD) and their average finish time was 673±25 minutes. All 4 
runners were male. They did not present to the medical tent at the race 
finish but became symptomatic 1 - 4 days post-race when hospitalised 
for management of ARF in the same local hospital. The exact incidence 
of ARF in finishers and non-finishers is unknown owing to the difficulty 
of tracking hospitalisations once runners leave the local area (Durban 
through Pietermaritzburg). Initial blood samples taken on hospital 
admission (Table I) showed that 3 of the runners were hyponatraemic 
(blood sodium concentrations <135 mEq/l), and 2 were hypochloraemic 
(blood chloride concentrations <98 mEq/l). Blood urea, creatinine and 
creatine phosphokinase (CPK) concentrations were elevated. Blood 
calcium concentrations were not measured.
All 4 athletes reported that they ingested the same readily available 
anti-cramp electrolyte supplement during the race; the estimated 
range of tablets ingested on race day varied from 6 to 16 tablets, 
with an average intake of 11 tablets (1 per hour) (Table II). Three 
runners ingested NSAIDs during the race, while patient 1 ingested 
an analgesic/muscle relaxant (Besemax; 450 mg paracetamol and 
35 mg orphenadrine citrate) during and Voltaren (NSAID) prior 
to the race for a knee injury. Three of the 4 runners reported 
vomiting in the period between race finish and hospital admission, 
while patient 3 reported developing nausea. Three of the runners 
were Comrades Marathon novices. Patient 4 was running his 7th 
Comrades Marathon, but his training had been curtailed in the 2 
months before the race, owing to a significant running injury (shin 
splints) and surgery for haemorrhoids.
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Objectives.  To  evaluate  common  factors  associated with  the 
development of acute renal failure (ARF) in Comrades Marathon 
runners.
Methods. This was a retrospective case series of 4 runners 
hospitalised post-race with ARF in the 89 km 2010 Comrades 
Marathon. The outcome measures were incidence of analgesic use, 
levels of creatine phosphokinase (CPK) and degree of electrolyte 
supplementation (sodium, potassium, calcium and magnesium).
Results. The prevalence of ARF was 1/4 125 runners. They 
presented with rhabdomyolysis (mean admission CPK of 36 294 
IU) and hyponatraemia (mean admission blood sodium level of 133 
mEq/l). All had ingested an analgesic during the run (3 ingested 
a non-steroidal anti-inflammatory drug) and the same readily 
available anti-cramp electrolyte supplement. The average amount 
of supplemental sodium (452 mg), potassium (393 mg), calcium 
(330 mg) and magnesium (154 mg) ingested via this particular 
electrolyte supplement before and during the run did not exceed 
the recommended upper limits of daily intake. Three of the runners 
were Comrades Marathon novices.
Conclusions. There is a continuing need to clarify the specific 
cluster variants that cause ARF in Comrades Marathon runners, 
as the risk factors appear to have evolved since the first case was 
described over 40 years ago.
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The estimated average and range of sodium, magnesium, calcium 
and potassium intake obtained via ingestion of the electrolyte 
supplement common to the runners is compared with adequate daily 
intake (AI), upper limit of intake (UL) and estimated electrolyte 
sweat loss in Table III.
Discussion 
This case series details the development of ARF in 4 male runners 
following completion of the 2010 Comrades Marathon, requiring 
hospitalisation and acute renal dialysis. More of the 16  500 race 
participants might have developed ARF; cases might have been 
undetected if the affected runners did not live in the catchment area 
surveyed by the Chief Medical Officer. The minimum prevalence of 
ARF in the 2010 Comrades Marathon was therefore 1/4 125 runners; 
this is an unusually high incidence compared with previous marathon 
years (‘typical’ incidence was 1/10 000 runners).1 
Factors known to be associated with ARF include rhabdomyolysis 
with elevated serum CPK usually in excess of 20 000 IU, although 
no clearly defined CPK ‘threshold’ exists where the risk of ARF is 
markedly increased.7 We previously described mean CPK values of 
between 637 and 1 878 IU in asymptomatic Comrades Marathon 
runners;8,9 the high values between 5 718 and 54 231 IU measured 
in the present cluster of runners with ARF appeared to be far 
above the normal range of healthy runners, indicative of marked 
rhabdomyolysis (Table I). 
Exercise-induced rhabdomyolysis – with mean CPK values 
exceeding 40 000 IU in: (i) 35 patients admitted to hospital with 
a primary or secondary diagnosis of rhabdomyolysis;10 and (ii) 
39 runners finishing a 246 km race11 – has not been shown to 
be diagnostic of impending renal failure. No cases of ARF were 
documented in either of the aforementioned studies despite the 
high CPK levels mimicking that of 2 of the 4 Comrades runners 
Table I. Case particulars including biochemical parameters (plasma concentrations: [ ]p) measured at hospital admission
Case
Age
(years)
Race finish time
(h:min)
Time between race finish
and hospital admission
(days)
[Na+] p
(mEq/l)
nl (135 - 145)
[K+]p
(mEq/l)
nl (3.5 - 5.4)
[Cl-]p
(mEq/l)
nl (98 - 106)
[Urea]p
(mg/dl)
nl (7 - 18)
[Creatinine]p
(µmol/l)
nl (60 - 110)
[CPK]p
(U/l)
nl (2 - 204)
1 38 10:45 2 133 4.8 99 30 656 48 934
2 24 11:06 1 133 3.8 99 13 264 Not measured
3 40 11:45 2 136 4.3 95 26 551 54 231
4 40 11:19 4 131 4.8 95 41 1 139 5 718
nl = normal range.
Table II. Self-reported data: body weight change, duration of dialysis, supplement and medication use, presence of vomiting, and 
prior Comrades Marathon experience
Case
Normal
body weight
(kg)
Body weight change
after dialysis
( +/- kg)
Duration of dialysis
(days)
Number of
electrolyte
tablets ingested
during race
NSAID
ingestion
during race
Vomiting
after race
Novice
Comrades Marathon
runner
1 66 - 6 21 6 No Yes Yes
2 65 + 7 15 16 Yes Yes Yes
3 81 - 4 10 8 Yes No Yes
4 75 + 9 2 11 Yes Yes No
Table III. Estimated electrolyte intake from the anti-cramp electrolyte supplement ingested by 4 runners who developed acute renal 
failure, compared with recommended daily dosages and upper limits of intake
Electrolyte
Average intake
mEq (mg)
(range of ingestion)
Adequate index
(AI)
mEq (mg)
Upper limit
 (UL)
mEq (mg)
Typical range
in sweat
mEq/l
Estimated
sweat loss*
mEq
Sodium
(Na+)
20 (452)
(11 - 29 (247 - 657)) 65 (1 500) 100 (2 300) 10 - 70 60 - 420
Magnesium 
(Mg2+)
17 (393)
(9 - 24 (214 - 571)) 17 (400) Not established 0.2 - 1.5 1.2 - 9
Calcium
(Ca2+)
8 (330)
(5 - 12 (180 - 480)) 25 (1 000) 63 (2 500) 0.3 - 2 1.8 - 12
Potassium
(K+)
4 (154)
(2 - 6 (84 - 224)) 120 (4 700) Not established 3 - 15 18 - 90
*Assuming that runners lost 500 ml of sweat per hour for 12 hours.
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with ARF in the present study. On the other hand, because CPK 
levels were not measured pre-race, we cannot rule out the presence 
(or absence) of undiagnosed subclinical metabolic myopathies in 
this cluster. McArdle’s syndrome, carnitine palmitoyltransferase 
deficiency, Becker’s syndrome, and disorders of caveolin-3 may be 
‘silent myopathies’ that only present with symptoms and elevated 
CPK levels following exercise.12
A second factor associated with ARF in endurance athletes is 
NSAID use, which was previously found in 79 - 80% of ARF cases 
in endurance athletes.4,13 Three of the 4 runners in the present study 
ingested NSAIDs during the 2010 Comrades Marathon: patients 2 
and 4 ingested 2 and 7 Cataflam tablets respectively; and patient 3 
ingested 3 Myprodol tablets. Patient 1 ingested 2 Besemax tablets 
during the race, as well as Voltaren for 1 week before the race to treat 
a knee injury. It is unclear what percentage of the 14 343 race finishers 
ingested NSAIDs during the race. An electronic survey of 2010 
Comrades Marathon participants showed that only ~6% of 3 367 
respondents indicated NSAID use either before or during the race 
(S. Rorke, personal communication). The much higher incidence of 
NSAID use in the runners who developed ARF compared with that 
of a ‘control’ group in the same race supports the role of NSAIDs 
as a clear ARF risk factor – even at mild non-prescription dosages. 
Investigations have confirmed significant changes in renal dynamics 
following ibuprofen ingestion.14 
A third factor associated with the development of ARF is exercise-
associated hyponatraemia (EAH), as recently shown in clusters of 
runners following 153 km and 161 km footraces.13,15 It has been 
postulated that cell swelling associated with EAH destabilises muscle 
cell membranes, making them less resistant to (traumatic) rupture. 
The proposed fragility of ‘swollen’ muscle cells then facilitates muscle 
breakdown, rhabdomyolysis and myoglobin release, leading to the 
development of ARF.13,15 
All 4 of the described runners were hyponatraemic on presentation 
to hospital 1 - 4 days after the race finish. This is probably the result 
of ARF, which can produce a dilutional hyponatraemia secondary 
to protracted anuria/oliguria.16 Serum sodium concentrations were 
not measured at the race finish; therefore it is unclear whether the 
documented hyponatraemia was either a cause or an effect of the 
exercise-associated ARF. 
Curiously, all 4 runners ingested the same commercially available 
electrolyte supplement marketed to prevent muscle cramps during 
exercise. None of them had previously taken this supplement. 
One serving size (2 tablets) (Table III) provides 300 mg of sodium 
bicarbonate, 250 mg of magnesium carbonate, 150 mg of calcium 
carbonate, 50 mg of potassium phosphate plus trace amounts of 
taurine (100 mg) and vitamin B6 (5 mg). The recommended product 
dosage was ingestion of 2 tablets 30 minutes before the start of the 
event, followed by 1 tablet each hour of exercise. Of the 4 electrolytes 
present in the supplement, sodium, potassium and calcium are the 
most likely to contribute to renal dysfunction. 
Sodium depletion, rather than supplementation, contributes to 
renal compromise via subsequent development of hyponatraemia, 
with or without volume depletion.17 It is unlikely that the 
supplemental sodium associated with ingestion of the described 
supplement contributed to the development of ARF or prevented the 
development of hyponatraemia in the 4 ARF patients. Furthermore, 
the absence of hyperkalaemia does not support excessive potassium 
ingestion as a contributing factor towards their development of ARF.
In contrast, the ingestion of large amounts of calcium plus 
absorbable alkali (‘milk-alkali syndrome’) (MAS) is a well-known 
cause of renal failure.18 MAS is characterised by hypercalcaemia 
and results from sustained intake of excessive amounts of calcium 
carbonate (~4 - 5 g per day).18 It appears unlikely that the amount of 
calcium carbonate ingested via the described electrolyte supplement 
– even in the highest self-reported dosage – could have contributed 
significantly to the development of ARF (Table III). Unfortunately, 
blood calcium concentrations were not measured in any of the 
affected runners. 
Conclusions
It appears that NSAID ingestion during the Comrades Marathon 
in runners with an (as yet) unidentified susceptibility produced 
rhabdomyolysis and ARF. Unexpectedly, all 4 runners ingested a 
specific anti-cramp electrolyte-containing supplement. The number 
of runners in the race who ingested this or similar supplements 
is unknown; however, this finding suggests that caution should 
be advised regarding liberal use of the product during prolonged 
exercise, despite ingested doses not reaching ‘toxic’ dosages, based 
on current AI or UL recommendations.19 There is a continuing 
need to determine the combination of factors which caused ARF 
to develop uniquely in only 4/16 500 runners. Accordingly, a better 
tracking system for reporting future adverse events should be 
implemented.
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